Revenue
2019
2020
2021
Quoin Pharmaceuticals, Ltd. (QNRX)
Price—Loading quote
Net income
2017
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2019
2020
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $0 | $0 | — |
| Research & development | $9.8M | $3.6M | $3.3M | $2.7M | $1.6M | $244,155 | $45,650 | $3.3M |
| Operating expenses | $16.3M | $9.5M | $9.4M | $9.3M | $6.1M | $1.7M | $1.6M | $7.0M |
| Operating income | — | — | — | — | — | −$4.4M | −$6.5M | −$7.0M |
| EBITDAderived | — | — | — | — | — | −$4.2M | −$6.4M | −$6.9M |
| Net income | −$15.8M | −$9.0M | −$8.7M | −$9.4M | −$21.5M | −$2.1M | −$1.6M | −$8.1M |
| Basic EPSper diluted share | — | — | — | — | -$0.01 | -$0.70 | -$0.52 | $0.07 |
| Diluted EPSper diluted share | — | — | — | — | -$0.01 | -$0.70 | -$0.52 | $0.07 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 14, 2025Form 4 | LANGER DENNISDirector | BuyADSs | 15.2K | $8.49 | $128.6K | 15.2K |
| Oct 14, 2025Form 4 | LANGER DENNISDirector | BuySeries K Warrants (Right to Buy) · derivative | 15.2K | — | — | 15.2K |
| Oct 14, 2025Form 4 | LANGER DENNISDirector | BuySeries J Warrants (Right to Buy) · derivative | 15.2K | — | — | 15.2K |
| Oct 14, 2025Form 4 | LANGER DENNISDirector | BuySeries I Warrants (Right to Buy) · derivative | 15.2K | — | — | 15.2K |
| Oct 14, 2025Form 4 | LANGER DENNISDirector | BuySeries H Warrants (Right to Buy) · derivative | 15.2K | — | — | 15.2K |